Top Page
DKS Co., Ltd.
(4461)
DKS Co., Ltd. (4461) vs. iShares MSCI Japan ETF (EWJ)
DKS Co., Ltd. Business Overview & Revenue Model
DKS Co., Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 74.77B | 73.25B | 63.12B | 65.08B | 62.67B | 59.14B |
| Gross Profit | 19.24B | 18.24B | 13.15B | 12.96B | 15.72B | 15.18B |
| EBITDA | 9.10B | 8.68B | 5.85B | 3.83B | 7.98B | 7.46B |
| Net Income | 2.96B | 2.58B | 1.17B | -407.00M | 2.49B | 2.56B |
Balance Sheet | ||||||
| Total Assets | 94.19B | 97.11B | 94.54B | 85.03B | 86.47B | 85.03B |
| Cash, Cash Equivalents and Short-Term Investments | 15.44B | 16.75B | 16.13B | 9.13B | 12.22B | 11.60B |
| Total Debt | 29.98B | 31.35B | 35.14B | 32.47B | 30.87B | 32.10B |
| Total Liabilities | 50.29B | 52.60B | 53.24B | 46.73B | 46.09B | 47.63B |
| Stockholders Equity | 38.95B | 38.73B | 36.75B | 34.35B | 36.77B | 34.65B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 5.39B | 4.59B | -2.11B | 2.86B | 557.00M |
| Operating Cash Flow | 0.00 | 7.53B | 7.09B | 724.00M | 5.52B | 4.96B |
| Investing Cash Flow | 0.00 | -2.14B | -2.01B | -2.88B | -2.70B | -3.80B |
| Financing Cash Flow | 0.00 | -5.04B | 1.65B | -1.03B | -2.34B | 255.00M |
DKS Co., Ltd. Technical Analysis
DKS Co., Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥30.66B | 11.79 | ― | 1.96% | 2.15% | 16.14% | |
75 Outperform | ¥85.37B | 28.81 | ― | 1.16% | 3.77% | 7.65% | |
74 Outperform | ¥35.78B | 4.16 | ― | 3.98% | 14.83% | 51.42% | |
73 Outperform | ¥29.74B | 13.88 | ― | 2.67% | -6.65% | -45.46% | |
70 Outperform | ¥43.41B | 18.36 | ― | 4.02% | 8.54% | 6.93% | |
69 Neutral | ¥74.71B | 19.47 | ― | 1.63% | 8.78% | 19.37% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
DKS Co., Ltd. Corporate Events
DKS Co. Ltd. and D. Western Therapeutics Institute, Inc. have announced positive results from their joint research project aimed at developing a treatment for dry eye. The collaboration, which began in December 2024, has confirmed the pharmacological effects of a synthesized compound in animal models, leading to an extension of their research agreement. This project is part of DKS’s efforts in its Life & Wellness segment to enhance research and development in the pharmaceutical field, with the goal of improving quality of life in an aging society. The joint research results will not impact the earnings forecast for the fiscal year ending March 2026.
The most recent analyst rating on (JP:4461) stock is a Buy with a Yen6677.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.
DKS Co., Ltd. has initiated a joint research project with Kyoto University to develop new drugs for neurodegenerative diseases, such as Parkinson’s and Alzheimer’s. This collaboration aims to evaluate the efficacy of DKS’s compounds and understand their mechanisms of action, with the goal of providing alternative treatments to existing symptomatic therapies. The research will utilize the Share Lab EVER SHIMOGAMO facility to enhance testing capabilities and foster collaboration with experts, thereby potentially improving the quality of life for patients.
The most recent analyst rating on (JP:4461) stock is a Buy with a Yen6677.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.
DKS Co., Ltd. has revised its financial and dividend forecasts for the fiscal year ending March 31, 2026, due to strong performance in its Electronics & IT and Environment & Energy segments. The company expects record-high profits, surpassing previous forecasts and targets set in its mid-term management plan ‘SMART 2030.’ Consequently, the annual dividend per share is projected to increase, reflecting the company’s commitment to stable shareholder returns.
The most recent analyst rating on (JP:4461) stock is a Buy with a Yen6677.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.
DKS Co., Ltd. reported strong financial results for the six months ending September 30, 2025, with a notable increase in net sales and profits compared to the previous year. The company revised its earnings and dividend forecasts upwards, indicating confidence in its continued growth and stability, which is likely to positively impact stakeholders and enhance its industry positioning.
The most recent analyst rating on (JP:4461) stock is a Buy with a Yen6677.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.
DKS Co., Ltd. has announced the disposal of treasury stock and a secondary offering of shares, with proceeds aimed at expanding production capacity for key products and repaying long-term borrowings. This strategic move is expected to enhance the company’s operational capabilities and strengthen its market position in the chemical industry.
The most recent analyst rating on (JP:4461) stock is a Hold with a Yen5720.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.
DKS Co., Ltd. announced the completion of an interim review of its consolidated financial results for the three months ending June 30, 2025, with notable increases in net sales and profits compared to the previous year. This review coincides with the company’s decision to dispose of treasury stock and conduct a secondary offering of shares, potentially impacting its financial strategy and shareholder value.
The most recent analyst rating on (JP:4461) stock is a Hold with a Yen5720.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.
DKS Co., Ltd. has announced the disposal of treasury stock to its Employee Shareholding Association as part of a Restricted Stock Incentive Plan. This initiative aims to enhance corporate value, foster managerial ownership, and support the company’s medium-term management plan, SMART 2030, by allowing eligible employees to acquire restricted stock.
The most recent analyst rating on (JP:4461) stock is a Hold with a Yen5720.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.
DKS Co., Ltd. announced the disposal of treasury stock and a secondary offering of shares to support its strategic initiatives and medium-term management plan, ‘SMART 2030.’ This move aims to strengthen the company’s financial base for future growth investments and maintain its inclusion in the TOPIX index by increasing the free float weight. The capital raised will be used for investments in key areas such as semiconductors, information and communications, and life sciences, aligning with the company’s goals to maximize mid- and long-term corporate value.
The most recent analyst rating on (JP:4461) stock is a Hold with a Yen5720.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.